Efficacy and Safety of Eraxis/Ecalta (Anidulafungin) Compared to Cancidas (Caspofungin) in Patients with Candida Deep Tissue Infection: A Phase 4 Study

-
Investigator: Peter Chin-Hong, MD
Sponsor: Pfizer

Location(s): United States

Description

The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.